Latest Depression News

Tryptamine Therapeutics has begun recruiting patients for a pioneering clinical trial testing IV-infused psilocin combined with psychotherapy to treat Binge Eating Disorder, aiming to deliver faster and more controlled treatment outcomes.

Burgundy Diamond Mines pauses open pit mining at Point Lake due to weak diamond prices, focusing instead on higher-margin underground operations at Misery. The company also prepares to unveil a new mine plan and Fox project study.

Prospect Resources has released compelling metallurgical test results from its Mumbezhi Copper Project in Zambia, demonstrating robust, high-grade copper concentrates and strong recoveries that support plans for a central processing hub.

Bowen Coking Coal Limited has had its ASX trading suspension lifted following its disclosure on funding efforts amid challenging market conditions. The company confirmed compliance with ASX rules, paving the way for immediate reinstatement.

Bowen Coking Coal Limited (BCB) has responded to ASX inquiries about its liquidity challenges, working capital needs from transitioning to an owner-operator model, and deteriorating operating margins, affirming compliance and financial viability despite market pressures.

Bowen Coking Coal has started owner-operated mining at its Burton Mine Complex with a reduced fleet and production focus, responding to weak global steel markets and low coal prices. The company is actively pursuing refinancing and strategic funding to sustain operations during this challenging period.

Clean Seas Seafood shareholders have voted to approve Yumbah Aquaculture’s acquisition scheme, setting the stage for delisting and a significant ownership change. The deal offers shareholders a cash option or a scrip alternative, with expert backing and board endorsement.

Legacy Minerals has acquired exploration rights to the Nico Young nickel-cobalt deposit in NSW, boasting one of Australia’s largest contained resources with significant strategic potential amid current market lows.

Bowen Coking Coal has announced it will remain suspended on the ASX as it reassesses its operational plans and explores financing options amid challenging market conditions.

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

Richmond Vanadium Technology slows key project activities and reshapes its leadership team to navigate a prolonged period of low vanadium prices while advancing battery technology development.

Bowen Coking Coal has surpassed its full-year 2025 production and sales targets ahead of schedule while transitioning the Burton Mine Complex to an owner-operator model. However, ongoing market challenges and funding uncertainties cast a shadow over its near-term outlook.